CD274 and neoplasm: PD-L1 expression in tumors and in lymphocytes and macrophages can be quantified through the combined positive score (CPS, defined by the number of PD-L1 staining cells (tumor cells) divided by the total number of viable tumor cells multiplied by 100) and is the current accompanying biomarker for the use of pembrolizumab in several solid tumors.